Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two agents, valproate (also known as valproic acid or sodium valproate) and creatine. Valproate is an anticonvulsant and mood stabilizer primarily used for the treatment of epilepsy, bipolar disorder, and migraine prophylaxis. Its mechanism involves increasing brain concentrations of gamma-aminobutyric acid (GABA), thereby exerting inhibitory effects on neuronal firing. Creatine is a naturally occurring compound involved in cellular energy metabolism, commonly used as a dietary supplement to enhance muscle performance and support neurological function. There are no approved pharmaceutical products combining these two agents; however, their interaction has been studied due to potential metabolic effects—valproate can disrupt creatine metabolism in the brain by causing hyperammonemia or through inhibition of enzymes involved in creatine synthesis and transport[1][2]. This may result in abnormal urinary excretion profiles for creatine metabolites.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valproate + creatine.